Parkinson's Disease/Movement Disorders News

The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in real time based on the patient’s brain activity, according to the manufacturer.

The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease progression over 96 weeks of treatment, according to a phase 3 study published in The Lancet.

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.

In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was associated with reduced incidence of Parkinson’s disease, data show.

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.

An automated machine-learning method that analyzed sleep movements recorded with a conventional 2D camera may improve diagnosis of rapid eye movement sleep behavior disorder, according to a study published in Annals of Neurology.

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in adults with Parkinson’s disease whose symptoms included fall risk and cognitive issues, data from JAMA Neurology show.

The average wait time between a referral and neurologist visit was more than a month among older adults, with longer wait times for those with serious neurodegenerative conditions like MS, epilepsy and Parkinson’s disease, new research shows.